Literature DB >> 12570838

Steroid 5alpha-reductase inhibitors.

Eugenio Flores1, Eugene Bratoeff, Marisa Cabeza, Elena Ramirez, Alexandra Quiroz, Ivonne Heuze.   

Abstract

The objective of this study is to synthesize new steroidal compounds based on the progesterone skeleton with a high inhibitory activity for the enzyme 5alpha-reductase. Presently similar compounds are being used for the treatment of androgen dependent diseases such as: hirsutism, androgenic alopecia, bening prostatic hyperplasia and prostate cancer. Dihydrotestosterone 2 (Fig. (1)), a 5alpha-reduced metabolite of testosterone 1 has been implicated as a causative factor in the progression of these diseases, largely through the clinical evaluation of males who are genetically deficient of steroid 5alpha-reductase enzyme. As a result of this study, the inhibition of this enzyme has become a pharmacological strategy for the design and synthesis of new antiandrogenic drugs. The advent of finasteride 8 (Fig. (4)) a 5alpha-reductase inhibitor has grately alleviated the symptoms associated with benign prostatic hyperplasia. In our laboratory we recently synthesized several new 16beta-methyl-pregnadiene-3,20-diones derivatives 27 (Fig.(6)), 38-42 (Fig. (11)), 16beta-phenyl-pregnadiene-3,17a-dione derivatives 32-33 (Fig. (7)), 16beta-phenyl-pregnatriene-3,17a-diones, 30, 31 (Fig. (7)) and 16beta-methyl-pregnatriene-3,20-diones 43-46 (Fig. (11)). These compounds were evaluated as 5alpha-reductase inhibitors in the following biological models: Penicillium crustosum broths, the flank organs of gonadectomized male hamsters, the incorporation of radiolabeled sodium acetate into lipids, the effect of the new steroids on the reduction of the weight of the seminal vesicles and on the in vitro metabolism of [(3)H]T to [(3)H]DHT in seminal vesicles homogenates of gonadectomized male hamsters. All trienones 30, 31, and 43-46 in all biological models showed consistently a higher 5alpha-reductase inhibitory activity than the corresponding dienones 27, 32, 33 and 38-42. We believe that with these compounds the 5alpha-reductase enzyme is inactivated by an irreversible Michael type addition of the nucleophilic portion of the enzyme to the conjugated double bond of the steroid. The trienones having a more coplanar structure react faster with the enzyme and thus show a higher inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570838     DOI: 10.2174/1389557033488196

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  6 in total

1.  Activity landscape analysis of novel 5α-reductase inhibitors.

Authors:  J Jesús Naveja; Francisco Cortés-Benítez; Eugene Bratoeff; José L Medina-Franco
Journal:  Mol Divers       Date:  2016-02-01       Impact factor: 2.943

Review 2.  Targeting cancer using cholesterol conjugates.

Authors:  Awwad A Radwan; Fares K Alanazi
Journal:  Saudi Pharm J       Date:  2013-01-31       Impact factor: 4.330

3.  Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels.

Authors:  Qin Wei; Robert Galbenus; Ashraf Raza; Ronald L Cerny; Melanie A Simpson
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

4.  Synthesis and 5α-reductase inhibitory activity of C₂₁ steroids having 1,4-diene or 4,6-diene 20-ones and 4-azasteroid 20-oximes.

Authors:  Sujeong Kim; Yong-ung Kim; Eunsook Ma
Journal:  Molecules       Date:  2011-12-30       Impact factor: 4.411

5.  Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Authors:  Fu-Ju Chou; Yuhchyau Chen; Dong Chen; Yuanjie Niu; Gonghui Li; Peter Keng; Shuyuan Yeh; Chawnshang Chang
Journal:  EBioMedicine       Date:  2019-01-26       Impact factor: 8.143

6.  Effect of dihydrotestosterone on mouse embryonic stem cells exposed to H2O2-induced oxidative stress.

Authors:  Mi Na Lee; Sang Hun Lee; Min Young Lee; Yun Hee Kim; Jae Hong Park; Jung Min Ryu; Seung Pil Yun; Yu Jin Lee; Mi Ok Kim; Kwangsung Park; Ho Jae Han
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.